Alkem Laboratories appoints Amrut Naik as CEO from November 11
In short
Alkem Laboratories has named Amrut Naik as its new CEO and Key Managerial Personnel, starting November 11, 2026. He previously worked at Zydus Group and Lupin and has more than 25 years in pharma.
This matters because it changes the company’s top leadership. The reporting does not say what strategy or business changes he will bring.
What the reporting says
Alkem Laboratories appointed former Zydus Group president Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective November 11, 2026, according to a publisher summary. The report says Naik has more than 25 years of pharmaceutical industry experience and has worked at Zydus and Lupin across emerging markets, acquisitions and strategic alliances. The immediate impact is a leadership change, while operational plans under his tenure are not stated.
Why it matters
The publisher summary says Alkem Laboratories appointed Amrut Naik as Chief Executive Officer and Key Managerial Personnel, effective November 11, 2026. It highlights his more than 25 years of pharmaceutical experience, including leadership roles at Zydus and Lupin, plus work across emerging markets, acquisitions and strategic alliances. The report does not state reasons for the appointment or any immediate business changes.